Open Access

Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations

  • Authors:
    • Naoto Sato
    • Yasushi Saga
    • Hiroaki Mizukami
    • Dongdong Wang
    • Hiroyuki Fujiwara
    • Yuji Takei
    • Shizuo Machida
    • Keiya Ozawa
    • Mitsuaki Suzuki
  • View Affiliations

  • Published online on: January 11, 2012     https://doi.org/10.3892/or.2012.1626
  • Pages: 1336-1340
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of this study was to explore the possibility of targeted molecular therapy with anti-epidermal growth factor receptor (anti-EGFR) antibody (cetuximab) for the treatment of mucinous ovarian carcinoma. We analyzed EGFR protein expression and KRAS gene mutations in 5 mucinous ovarian carcinoma cell lines RMUG-L, RMUG-S, MN-1, OMC-1 and MCAS and evaluated the in vitro and in vivo effects of cetuximab on each. EGFR expression was observed in all cell lines except for MN-1 cells, and a KRAS gene mutation at codon 12 was detected only in the MCAS cell line. Cetuximab inhibited RMUG-L and OMC-1 cell growth in vitro and completely blocked RMUG-L tumor growth in vivo. On the other hand, cetuximab did not affect MCAS cell growth in vitro and only partially reduced the MCAS tumor growth in vivo. These results suggest the possibility of targeted molecular therapy with cetuximab for mucinous ovarian carcinoma cells lacking a KRAS gene mutation.

Related Articles

Journal Cover

May 2012
Volume 27 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sato N, Saga Y, Mizukami H, Wang D, Fujiwara H, Takei Y, Machida S, Ozawa K and Suzuki M: Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations. Oncol Rep 27: 1336-1340, 2012.
APA
Sato, N., Saga, Y., Mizukami, H., Wang, D., Fujiwara, H., Takei, Y. ... Suzuki, M. (2012). Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations. Oncology Reports, 27, 1336-1340. https://doi.org/10.3892/or.2012.1626
MLA
Sato, N., Saga, Y., Mizukami, H., Wang, D., Fujiwara, H., Takei, Y., Machida, S., Ozawa, K., Suzuki, M."Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations". Oncology Reports 27.5 (2012): 1336-1340.
Chicago
Sato, N., Saga, Y., Mizukami, H., Wang, D., Fujiwara, H., Takei, Y., Machida, S., Ozawa, K., Suzuki, M."Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations". Oncology Reports 27, no. 5 (2012): 1336-1340. https://doi.org/10.3892/or.2012.1626